Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

821. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis

Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Desbiens N A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was anticoagulation treatment with warfarin in patients with nonrheumatic atrial fibrillation (AF). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients aged 65 to 100 years with nonrheumatic AF. Setting

NHS Economic Evaluation Database.2002

822. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Lumer G B, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagne P, Nattel S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Low-dose amiodarone was compared with other first-line therapy (sotalol or propafenone) for the treatment of atrial fibrillation (AF). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2002

823. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery

An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery Reddy P, Dunn A B, White C M, Tsikouris J P, Giri S, Kluger J Record Status This is a critical abstract of an economic evaluation that meets (...) reported. A sample size of 100 patients per group was needed to assure 0.80 power in the detection of a 50% difference in postoperative atrial fibrillation rate, with an anticipated 33% rate in the placebo group. A total of 220 patients (168 men, 52 women) were included in the study, with an approximate 10% drop-out rate anticipated after selection. Of these, 120 (74 men) were assigned to the amiodarone group (receiving amiodarone plus beta-blockers) and the remaining 100 (94 men) to the placebo group

NHS Economic Evaluation Database.2002

824. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation

Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Mahoney E M, Thompson T D, Veledar E, Williams J, Weintraub W S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prophylactic intravenous (IV) amiodarone therapy for the prevention of atrial fibrillation (AF) in patients undergoing cardiac surgery. Type of intervention Secondary prevention. Economic study type

NHS Economic Evaluation Database.2002

825. A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin

A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin Kim M H, Morady F, Conlon B, Kronick S, Lowell M (...) , Bruckman D, Armstrong W F, Eagle K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two approaches for the management of low-risk patients with newly diagnosed or new-onset atrial fibrillation (AF) were examined. The approaches were

NHS Economic Evaluation Database.2002

826. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) artery bypass grafting Kim M H, Rachwal W, McHale C, Bruckman D, Decena B F, Russman P, Morady F, Eagle K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A clinical pathway for the secondary prevention of postoperative atrial fibrillation (AF) in

NHS Economic Evaluation Database.2002

827. The maze procedure in treating atrial fibrillation

The maze procedure in treating atrial fibrillation The maze procedure in treating atrial fibrillation We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services The maze procedure in treating atrial fibrillation Share: Reading time approx. 10 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings (...) by SBU Alert Version: 1 Technology and target group Atrial fibrillation is a common disorder that impairs cardiac function and increases the risk for thrombosis. Primarily, medication is used to treat the disorder, but surgery becomes an option if medication or other non-pharmacological treatment alternatives are insufficient. The Maze procedure is an open surgical intervention that can be used to treat particularly severe cases of atrial fibrillation. Eleven incisions are strategically placed

Swedish Council on Technology Assessement2002

828. A comparison of rate control and rhythm control in patients with atrial fibrillation.

A comparison of rate control and rhythm control in patients with atrial fibrillation. 12466506 2002 12 05 2002 12 11 2013 11 21 1533-4406 347 23 2002 Dec 05 The New England journal of medicine N. Engl. J. Med. A comparison of rate control and rhythm control in patients with atrial fibrillation. 1825-33 There are two approaches to the treatment of atrial fibrillation: one is cardioversion and treatment with antiarrhythmic drugs to maintain sinus rhythm, and the other is the use of rate (...) -controlling drugs, allowing atrial fibrillation to persist. In both approaches, the use of anticoagulant drugs is recommended. We conducted a randomized, multicenter comparison of these two treatment strategies in patients with atrial fibrillation and a high risk of stroke or death. The primary end point was overall mortality. A total of 4060 patients (mean [+/-SD] age, 69.7+/-9.0 years) were enrolled in the study; 70.8 percent had a history of hypertension, and 38.2 percent had coronary

NEJM2002

829. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. 12466507 2002 12 05 2002 12 11 2006 11 15 1533-4406 347 23 2002 Dec 05 The New England journal of medicine N. Engl. J. Med. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. 1834-40 Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side (...) effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation. We randomly assigned 522 patients who had persistent atrial fibrillation after a previous electrical cardioversion to receive treatment aimed at rate control or rhythm control. Patients in the rate-control group received oral anticoagulant drugs and rate-slowing medication. Patients in the rhythm

NEJM2002

830. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial.

Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. 12414201 2002 11 04 2002 12 04 2015 06 16 0140-6736 360 9342 2002 Oct 26 Lancet (London, England) Lancet Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. 1275-9 External cardioversion is a readily available treatment for persistent atrial fibrillation. Although anatomical (...) and electrophysiological considerations suggest that an anterior-posterior electrode position should create a more homogeneous shock-field gradient throughout the atria than an anterior-lateral position, both electrode positions are equally recommended for external cardioversion in current guidelines. We undertook a randomised trial comparing the two positions with the endpoint of successful cardioversion. 108 consecutive patients (mean age 60 years [SD 16]) with persistent atrial fibrillation (median duration 5

Lancet2002

831. Electrical cardioversion for atrial fibrillation and flutter.

Electrical cardioversion for atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation increases the risk of stroke, increases the risk of cognitive impairment, and adversely affects cardiovascular haemodynamics. Electrical cardioversion for atrial fibrillation has been in use since the 1960s; the rationale is that restoration of sinus rhythm improves cardiovascular haemodynamics, reduces the risk of stroke, and obviates the need for long-term anticoagulation. OBJECTIVES: To assess (...) the effects of electrical cardioversion of atrial fibrillation or atrial flutter on the annual risk of thromboembolic events, strokes and mortality (primary outcomes measures), the rate of cognitive decline, quality of life, the use of anticoagulants and the risk of re-hospitalisation (secondary outcome measures) in adults (>18 years) with acute, paroxysmal or sustained atrial fibrillation or atrial flutter, of any duration and any aetiology. SEARCH STRATEGY: One reviewer searched the Cochrane

Cochrane2002

832. Atrial fibrillation after cardiac surgery.

Atrial fibrillation after cardiac surgery. PURPOSE: To review the epidemiology, mechanisms, complications, predictors, prevention, and treatment of atrial fibrillation following cardiac surgery. DATA SOURCES: MEDLINE search of English-language reports published between 1966 and 2000 and a search of references of relevant papers. STUDY SELECTION: Clinical and basic research studies on atrial fibrillation after cardiac surgery. DATA EXTRACTION: Relevant clinical information was extracted from (...) selected articles. DATA SYNTHESIS: Atrial fibrillation occurs in 10% to 65% of patients after cardiac surgery, usually on the second or third postoperative day. Postoperative atrial fibrillation is associated with increased morbidity and mortality and longer, more expensive hospital stays. Prophylactic use of beta-adrenergic blockers reduces the incidence of postoperative atrial fibrillation and should be administered before and after cardiac surgery to all patients without contraindication

Annals of Internal Medicine2001

833. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. OBJECTIVE: To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation. DESIGN: Prospective observational study. SETTING: Tertiary and peripheral referral centres in Nova Scotia, Canada (...) . PARTICIPANTS: 63 physicians who were treating patients with atrial fibrillation and 61 patients at high risk for atrial fibrillation. MAIN OUTCOME MEASURES: Participants underwent a face to face interview with a probability trade-off tool. Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation. RESULTS: The minimum number of strokes that needed

BMJ2001 Full Text: Link to full Text with Trip Pro

834. Management of new onset atrial fibrillation

Management of new onset atrial fibrillation Management of new onset atrial fibrillation Management of new onset atrial fibrillation McNamara R L, Bass E B, Miller M R, Segal J B, Goodman S N, Kim N L, Robinson K A, Powe N R Authors' objectives To synthesise the evidence that exists to guide clinicians in the management of patients with new onset atrial fibrillation (AF). The key questions to be addressed were identified as follows. Which patients should receive cardioversion and which should (...) receive conservative treatment with rate control and thromboembolism prophylaxis? What is the efficacy of electrical cardioversion alone versus anti-arrhythmic treatment alone versus both together in this patient group? What are the risks and benefits of each anti-arrhythmic agent used for conversion of AF and/or the maintenance of sinus rhythm after successful cardioversion? What types of therapy for AF can be performed safely in an out-patient rather than an in-patient setting? What

DARE.2001

835. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence

Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence Slavik R S, Tisdale J E, Borzak S Authors' objectives To evaluate the efficacy of currently available anti-arrhythmic agents for the conversion of atrial fibrillation (AF) to normal sinus rhythm (NSR). Searching MEDLINE (from (...) of evaluations included in the review The inclusion criteria were not defined a priori in terms of the study design. The included studies were: randomised placebo-controlled trials; randomised comparative trials; prospective, non-randomised comparative trials; prospective cohort trials; reviews of retrospective data; and case series. Specific interventions included in the review Treatments with anti-arrhythmic agents specifically aimed at converting AF to NSR were eligible. Drugs that were currently

DARE.2001

836. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation

Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Taylor F C, Cohen H, Ebrahim S Authors' objectives To examine the benefits and risks of long-term anticoagulation (warfarin (...) ) compared with antiplatelet treatment (aspirin, indobufen) in patients with non-rheumatic atrial fibrillation. Searching The CENTRAL Register on the Cochrane Library, EMBASE, MEDLINE, CINAHL and SIGLE were searched from 1966 to 1999 using the terms 'atherosclerosis', 'atrial fibrillation', 'myocardial infarction' or 'coronary disease' and 'anticoagulation' and a RCT filter (see Other Publications of Related Interest no.1). In addition, the authors checked references in relevant papers and approached key

DARE.2001

837. Management of new onset atrial fibrillation

Management of new onset atrial fibrillation Management of new onset atrial fibrillation Management of new onset atrial fibrillation McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, Robinson KA, Powe NR Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, Robinson KA (...) , Powe NR. Management of new onset atrial fibrillation. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 12. 2001 Authors' objectives Atrial fibrillation (AF) is the most common arrhythmia physicians face in clinical practice, with an incidence of up to 2.3% per year and a prevalence of almost 9% in those aged 80-89 years. In addition to having various symptoms, patients with AF have increased risk for stroke and death. This report synthesizes

Health Technology Assessment (HTA) Database.2001

838. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.

Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. 11265951 2001 03 26 2001 04 12 2015 06 16 0140-6736 357 9259 2001 Mar 17 Lancet (London, England) Lancet Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. 830-6 Beta-blockers and amiodarone reduce (...) the frequency of atrial fibrillation after open-heart surgery but the effectiveness of oral amiodarone in older patients already receiving beta-blockers is unknown. We have assessed the efficacy of oral amiodarone in preventing atrial fibrillation in patients aged 60 years or older undergoing open-heart surgery. We did a randomised, double-blind placebo-controlled trial in which patients undergoing open-heart surgery (n=220, average age 73 years) received amiodarone (n=120) or placebo (n=100). Patients

Lancet2001

839. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. 11346805 2001 04 26 2001 05 21 2016 11 24 0028-4793 344 19 2001 May 10 The New England journal of medicine N. Engl. J. Med. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. 1411-20 The conventional treatment strategy for patients with atrial fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulation (...) for three weeks before cardioversion. It has been proposed that if transesophageal echocardiography reveals no atrial thrombus, cardioversion may be performed safely after only a short period of anticoagulant therapy. In a multicenter, randomized, prospective clinical trial, we enrolled 1222 patients with atrial fibrillation of more than two days' duration and assigned them to either treatment guided by the findings on transesophageal echocardiography or conventional treatment. The composite primary end

NEJM2001

840. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. BACKGROUND: Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use. OBJECTIVES: To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated for prevention (...) of thromboembolism in AF. SEARCH STRATEGY: Articles were identified through the Cochrane Collaboration's CENTRAL database and MEDLINE until December 1999. SELECTION CRITERIA: Included Randomized controlled trials of drugs to prevent thromboembolism in adults with non-postoperative AF. Excluded RCTS of patients with rheumatic valvular disease. DATA COLLECTION AND ANALYSIS: Data were abstracted by two reviewers. Odds ratios from all qualitatively similar studies were combined, with weighting by study size

Cochrane2001